Galectin Therapeutics Inc.
GALT
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with faā¦ read more
Healthcare
Biotechnology
23 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.25
Price+2.12%
$0.09
1Y
Price
Market Cap
$273.516m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$37.303m
+20.7%
1y CAGR+0.1%
3y CAGR-6.7%
5y CAGREPS
-$0.59
+22.4%
1y CAGR+1.9%
3y CAGR-4.8%
5y CAGRBook Value
-$125.303m
$12.865m
Assets$138.168m
Liabilities$122.312m
DebtDebt to Assets
950.7%
-4x
Debt to EBITDAFree Cash Flow
-$30.624m
+26.7%
1y CAGR-2.1%
3y CAGR-8.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company